1. United States of America Stocks

  2. •

    Financial Services

  3. •

    Shell Companies
Moringa Acquisition Corp

Moringa Acquisition Corp

MACA
Moringa Acquisition CorpUS flagNASDAQ Capital Market
9.46
USD
-1.50
- -
36.61MMarket Cap
Moringa Acquisition Corp
MACA
(NASDAQ Capital Market)

Recent

price

9.46

P/E

ratio

- -

div

yld

- -

ROIC.AI

2020
2021
2022
2023
TTM
FRC
- -
- -
- -
- -
- -
Revenue per Share
- -
-0.23
0.17
0.08
-0.16
Basic EPS, GAAP
- -
-0.43
0.24
0.09
-0.17
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
Dividend per Share
- -
34.54
34.42
0.85
0.76
Book Value per Share
- -
34.8
34.42
0.85
0.76
Tangible Book Value per Share
- -
3
3
3
3
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
Depreciation Expense
- -
-1
1
- -
-1
Net Income, GAAP
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
Profit Margin (%)
- -
115
117
6
6
Working Capital
- -
- -
1
3
3
LT Debt
- -
115
115
3
3
Total Equity
- -
- -
-1.06
-1.82
-2.05
Return on Invested Capital (%)
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
0.51
0.44
-3.78
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'23
Mar'24
Jun'24
ST Debt
- -
- -
- -
LT Borrowings
3
3
3
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
4
4
4
Market Capitalization
36
38
39

Working Capital

FRC

•

in mil. unless spec.
Dec'23
Mar'24
Jun'24
Total Current Assets
6
6
6
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
- -
- -
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-97.53%
Free Cash Flow
- -
- -
-62.47%
Net Income, GAAP
- -
- -
-54.96%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
-0.07
0.01
0.09
- -
0.17
2023
0.09
0.05
0.02
- -
0.08
2024
-0.06
-0.03
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
Similar Companies
NMP Acquisition Corp. (NMP)
Iconic Sports Acquisition Corp. (ICNC-WT)
Glenfarne Merger Corp. (GGMCW)
Research Alliance Corporation III Class A Ordinary Shares (RACC)
Tribeca Strategic Acquisition Corp. (BID)
Tuscan Holdings Corp. (THCBU)
Business
Moringa Acquisition Corp is a special purpose acquisition company (SPAC) based in New York, established in 2020, primarily focused on acquiring or merging with innovative technology and biotechnology companies. It engages in strategic business combinations including mergers, share exchanges, asset acquisitions, and recapitalizations. The company’s notable recent business combination involved a reverse merger with Silexion Therapeutics Ltd., a clinical-stage, oncology-focused biotechnology company specializing in the development of siRNA-based therapies targeting solid tumor cancers with mutated KRAS oncogenes. Through this combination completed in August 2024, Moringa Acquisition Corp transitioned from a SPAC entity to a publicly listed biotechnology firm under Silexion Therapeutics. Its main offerings now include advancing therapeutic innovations for solid tumor cancers, conducting clinical trials, and developing oncology drug candidates, with a focus on locally advanced pancreatic cancer treatment. This transaction granted the combined company enhanced financial and strategic flexibility to pursue siRNA therapeutic development. Moringa Acquisition Corp originally focused on technology-based acquisitions primarily in Israel but has shifted its operations towards clinical biotechnology and oncology therapeutics through its merger with Silexion. The company trades on Nasdaq under the ticker MACA until the merger, with its successor listed under new tickers. This strategic shift exemplifies its expansion from a financial acquisition vehicle to an operational biotech firm targeting unmet needs in cancer therapies.

Company News

Company News APIChatGPT

  • globenewswire.com

    Silexion, a Clinical-Stage, Oncology-Focused Biotechnology Company, to Become Publicly Traded Via Business Combination with Moringa Acquisition Corp

  • globenewswire.com

    MORINGA ACQUISITION CORP ANNOUNCES CONTRIBUTION TO TRUST ACCOUNT IN CONNECTION WITH PROPOSED EXTENSION